Will Malin stock go up?

According to Danelfin AI, Malin has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (46.54%) is -3.06% vs. the average probability (49.60%) of all European stocks.

Is it a good time to buy, sell, or hold Malin stock right now?

Malin has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (46.54%) is -3.06% vs. the average probability (49.60%) of all European stocks, based on our AI-powered analysis. You can find more details on whether Malin stock is a good buy .

What is going on with Malin stock in the last 3 months?

The Malin stock performance in the last quarter has been -5.84%.

Does Malin offer dividend payments?

No, Malin does not currently pay dividends.

What is the current market capitalization of Malin?

Malin's market cap is €32.23M, as of 2026-07-03 08:00.

Malin Corporation PLC (MLC.IR) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

MLC.IR AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+3.33%
Direction and strength of recent price movements
Valuation+1.41%
How the stock is priced relative to its fundamentals
Size & Liquidity+0.24%
Company size and trading liquidity

Sentiment-3.82%
How analysts and the market view the stock
Volatility-1.15%
How much the stock price tends to fluctuate
Growth-0.97%
Expected pace of revenue and earnings expansion
Earnings Quality-0.80%
Stability and reliability of reported earnings
Financial Strength-0.71%
Balance sheet strength and financial resilience
Profitability-0.59%
Profitability and operating efficiency metrics

MLC.IR probability advantage of beating the market (3M):

-3.06%

AI Score

Hold

Malin (MLC.IR) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -3.06% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.60%) and the probability of MLC.IR (46.54%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.60%
MLC.IR probability advantage of beating the market (3M)-3.06%
MLC.IR probability of beating the market (3M)46.54%

MLC.IR probability advantage of beating the market (3M): -3.06%

The AI-powered overall analysis of Malin (MLC.IR) is based on the 32 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of MLC.IR:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Life Sciences Tools & Services	N/A	-4.42%
Technical	Avg. Last Decile Drawdown (1Y)	-0.07		-1.87%
Technical	Chart Pattern (180d)	figure_90	N/A	+1.28%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.21%
Fundamental	Diluted EPS	0		-0.97%
Fundamental	Consolidated Net Income / Loss	0		-0.80%
Technical	Alpha YTD	-0.15%		+0.74%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.73%
Fundamental	Other Current Assets QoQ Growth	-1.00%		-0.65%
Technical	Chart Pattern (252d)	figure_1	N/A	-0.56%
Fundamental	Upgrade to unlock			-0.50%
Technical	Upgrade to unlock			-0.48%
Fundamental	Upgrade to unlock			-0.42%
Fundamental	Upgrade to unlock			-0.41%
Technical	Upgrade to unlock			+0.39%

Rest of Alpha Signals: +3.68%

MLC.IR probability advantage of beating the market (3M)Total:-3.06%
MLC.IR AI Score

Significant changes Vs previous day

MLC.IR Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:€7.25
Horizon: 3 months
Stop Loss:€XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:€XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

MLC.IR Proven Hold Signal & Price Forecast

This is the price chart for MLC.IR from January 2, 2026 until today. The chart indicates, in yellow, the 47 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

MLC.IR Average Past Performance & Win Rate

Three months after its 841 Hold signals since July 2026, MLC.IR had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

841 Past MLC.IR Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+20.75%
Average Alpha				0.00%
Win Rate (% Positive Perf.)				57.50%
% Positive Alpha				0.00%

MLC.IR Frequently Asked Questions

Will Malin stock go up?
According to Danelfin AI, Malin has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (46.54%) is -3.06% vs. the average probability (49.60%) of all European stocks.
Is it a good time to buy, sell, or hold Malin stock right now?
What is going on with Malin stock in the last 3 months?
Does Malin offer dividend payments?
What is the current market capitalization of Malin?

Malin Corporation PLC Company Profile

Malin Corporation PLC (MLC.IR) is an Irish investment company that partners with and invests in private and public life sciences companies. It focuses on developing and commercializing therapeutic and diagnostic products designed to address significant unmet medical needs. The company aims to create shareholder value by identifying and supporting innovative healthcare businesses across various stages of development, from early-stage research to commercialization.

The company's investment strategy targets a diverse range of life sciences sub-sectors. These include biopharmaceuticals, medical technologies, and diagnostics, encompassing both novel drug candidates and advanced medical devices. Malin provides capital, strategic guidance, and operational support to its portfolio companies. This comprehensive support helps them advance their research, clinical development, and commercialization efforts efficiently and effectively.

Malin's portfolio companies operate across various therapeutic areas, addressing complex diseases and conditions. These areas often include oncology, immunology, rare diseases, and infectious diseases, among others. The company seeks businesses with strong scientific foundations, proprietary technologies, and clear pathways to market. It emphasizes building long-term partnerships to foster sustainable growth and innovation within its investments.

Malin actively manages its portfolio, working closely with company management teams to enhance value and mitigate risks. This involvement aims to optimize operational performance, refine strategic direction, and strengthen market positioning. The company's approach seeks to accelerate the delivery of novel healthcare solutions to patients worldwide. It focuses on opportunities with potential for substantial clinical impact and commercial success.

Malin primarily serves its shareholders through its investment activities. Its portfolio companies, in turn, serve patients, healthcare providers, and research institutions globally. The company generates revenue primarily from capital gains and investment returns, with some recurring income from dividends and licensing agreements, operating through direct investments and strategic partnerships with a global reach.

Sector:Health Care
Country:Ireland
Industry:
Address:The Lennox Building, 50 Richmond Street South, DUBLIN
Employees:2
Website:malinplc.com

Pros

Diversified investment portfolio across life science modalities

Proprietary deal sourcing capabilities in biotechnology

Exposure to long-term healthcare demand growth

Potential for outsized returns from successful product commercialization

Active value creation through portfolio company support

Cons

Extended development timelines for therapeutic assets

Substantial capital requirements for clinical stage companies

High regulatory approval risk for novel medical products

Illiquidity of private equity investments

Valuation complexity of early-stage life science assets

Pros

Cons

Company

AI Score

Compare

PHM.MCPharma Mar SA

MARI.VIMarinomed Biotech AG

ACE.STAscelia Pharma AB

AZN.LAstraZeneca PLC

Company

AI Score

Compare

MLC.IR Top 10 Industry Stocks

Life Sciences Tools & Services

	Company	AI Score	Compare
1	PANG.MCPangaea Oncology SA
2	SFZN.SWSiegfried Holding AG
3	DXRX.LDiaceutics PLC
4	DIM.PASartorius Stedim Biotech SA
5	ERF.PAEurofins Scientific SE
6	BANB.SWBachem Holding AG
7	MLC.IRMalin Corporation PLC
8	CHEMM.COChemometec A/S
9	GUBRA.COGubra A/S
10	HEN.WA

	Company	AI Score	Compare

MLC.IR Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	FAE.MCFaes Farma SA
2	REC.MIRecordati Industria Chimica e Farmaceutica SpA
3	ALK B.COALK-Abello A/S
4	ANCR.LAnimalcare Group plc
5	MPARK.E.ISMLP Saglik Hizmetleri AS
6	PRM.MCPrim SA
7	DMP.DEDermapharm Holding SE
8	TRILC.E.ISTurk Ilac ve Serum Sanayi AS
9	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
10	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS

	Company	AI Score	Compare

MLC.IR Stock AI Analysis